Reply and AWS Announce Multi-Year Strategic Collaboration to Advance Generative AI Innovations, Helping Customers Design, Develop, and Deploy Scalable and Secure AI Applications
The new collaboration will drive the development and application of Generative AI solutions across industries, leveraging AWS services and Reply’s AI expertise.
Reply, a global leader in systems integration and consulting, today announced a multi-year strategic collaboration agreement with Amazon Web Services (AWS) to accelerate innovation in Generative Artificial Intelligence (GenAI). This collaboration will enable businesses worldwide to harness the power of AI by leveraging advanced cloud infrastructure and AI-driven capabilities. Together, Reply, with its companies Data Reply and Storm Reply, and AWS aim to create vertical solutions that increase process efficiency and boost productivity, and build specialized GenAI offerings spanning various industries and use cases.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325287170/en/

Reply provides solutions on AWS starting from digital transformation consultancy to managed services. The new collaboration will drive the development and application of Generative AI solutions across industries, leveraging AWS services and Reply’s AI expertise.
The collaboration builds on a long-standing relationship between Reply and AWS. Over the years, Reply has been at the forefront of AI innovation with AWS, achieving the AWS Machine Learning Competency in 2020, gaining preview access to Amazon Bedrock in 2023, and being one of the first companies worldwide to earn the AWSGenerative AI Competency in 2024.
“We are thrilled to expand our collaboration with AWS to explore the full potential of Generative AI,” said Filippo Rizzante, CTO at Reply. “Our combined efforts will merge advanced AWS technology with Reply’s AI expertise to deliver transformative solutions for our clients. This collaboration not only reflects our dedication to innovation but also our commitment to helping organizations stay ahead in a rapidly evolving digital landscape.”
With this collaboration, Reply will enable its customers to efficiently adopt AWS, embracing AI at scale with a secure and streamlined approach. The Reply’s companies, Data Reply and Storm Reply, will deploy the advanced AI and machine learning services of AWS, including Amazon SageMaker, Amazon Bedrock, and Amazon Q, to design, develop, and deploy scalable and secure Generative AI applications for diverse use cases, including software engineering optimization, hyper-personalized customer experiences, operational efficiency, intelligent cost optimization, AI-driven operations, and sales and marketing automation.
As part of the agreement, Data Reply and Storm Reply will gain access to specialized training and resources. This initiative will empower them to deliver tailored AI solutions for clients across markets, with a specific focus on Automotive, FSI and Energy.
Reply’s expertise in AI is exemplified through several solutions, addressing concrete business challenges across various domains, including knowledge management, software development, customer engagement, supply chain optimization, security, and social media management. These solutions leverage advanced GenAI Agentic capabilities to deliver valuable results, such as:
- enhancing decision-making processes by enabling AI systems to intelligently integrate and analyze data from multiple knowledge sources for deeper insights.
- optimizing enterprise operations by seamlessly integrating AI with core business systems, enabling automated data processing in areas such as human resources, finance, supply chain management, and customer service to improve efficiency and streamline workflows.
- advancing market intelligence with AI-driven solutions that autonomously gather, analyze, and synthesize real-time market data into actionable insights, enabling businesses to stay ahead in dynamic markets.
Reply’s expertise translates into practical use cases for customers worldwide. For example, Storm Reply has partnered with Audi to enhance internal documentation processes using a RAG-based AI chatbot, streamlining document management and retrieval while improving operational efficiency. Additionally, Il Sole 24 Ore, one of Italy’s leading publishing groups, collaborated with Storm Reply and AWS to transform its renowned "L’Esperto Risponde" service using Generative AI. This solution, powered by Amazon Bedrock, enables experts to interact seamlessly with a knowledge base of over 130,000 documents, automating draft responses while maintaining high accuracy and significantly reducing response times.
As part of its continuous effort to push the boundaries of AI, Reply is also developing GenAI solutions leveraging Anthropic's Claude models on AWS. Anthropic's Claude models provide safe and reliable outputs aligned with user prompts, avoiding harmful activities. These models are integrated into Amazon Bedrock for secure data access. By combining Anthropic's Claude powerful models, AWS’s secure infrastructure, and Reply’s AI expertise, customers can benefit from unprecedented value.
"We're excited to bring advanced AI technologies and cloud capabilities to our expanded relationship with Reply. Together, we look forward to providing customers with choice, flexibility, and security when building and scaling with generative AI on AWS," said Antonio Alonso Lopez, Director of Partner Management for EMEA at Amazon Web Services. "Reply's deep technical expertise will help customers swiftly and responsibly deploy AI-powered applications that drive business transformation and accelerate innovation across multiple industries."
The collaboration aligns with Reply’s mission to remain at the forefront of AI innovation and digital transformation. As an AWS Premier Consulting Partner, Reply’s companies specialized in AWS technologies – Airwalk Reply, Comsysto Reply, Concept Reply, Data Reply, Discovery Reply, Retail Reply, Sense Reply, and Storm Reply – continue to deliver customized solutions and services that leverage AWS technologies to address clients’ unique challenges and drive substantial business outcomes.
Visit the website for more information about Reply and AWS’s strategic collaboration and their commitment to advancing Generative AI.
Reply
Reply [EXM, STAR: REY, ISIN: IT0005282865] specializes in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialized companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325287170/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release
Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release
Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release
Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 114.5.2025 23:03:00 CEST | Press release
–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated–Oveporexton Found to be Generally Safe and Well Tolerated–Phase 3 Readout of Oveporexton Anticipated in 2025 Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo thro
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 22:05:00 CEST | Press release
Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignanciesFour oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation scie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom